Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
Roussel,M., Lauwers-Cances,V., Macro,M., Leleu,X., Royer,B., Hulin,C., Karlin,L., Perrot,A., Touzeau,C., Chretien,M.L., Rigaudeau,S., Dib,M., Nicolas-Virelizier,E., Escoffre-Barbe,M., Belhadj,K., Mariette,C., Stoppa,A.M., Araujo,C., Doyen,C., Fontan,J., Kolb,B., Garderet,L., Brechignac,S., Malfuson,J.V., Jaccard,A., Lenain,P., Borel,C., Hebraud,B., Benbrahim,O., Dorvaux,V., Manier,S., Augeul-Meunier,K., Vekemans,M.C., Randriamalala,E., Chaoui,D., Caers,J., Chaleteix,C., Benboubker,L., Vincent,L., Glaisner,S., Zunic,P., Slama,B., Eveillard,J.R., Humbrecht-Kraut,C., Morel,V., Mineur,P., Eisenmann,J.C., Demarquette,H., Richez,V., Vignon,M., Caillot,D., Facon,T., Moreau,P., Colin,A.L., Olivier,P., Wuilleme,S., Avet-Loiseau,H., Corre,J., Attal,M.
Revue : Blood -
2022 /
5
Volume : 139
Pages : 2747-2757